Skip to content

Category: Biotechnology

Nexsen Limited (ASX:NXN) Successfully Lists on the ASX Following $8 Million Initial Public Offering

By API User

14 October 2025 – Sydney, Australia | Nexsen Limited (ASX:NXN), an Australian nano-biotechnology company developing a next-generation point-of-care diagnostic platform, has today commenced trading on the Australian Securities Exchange (ASX) following a successful $8 million capital raising as part of its Initial Public Offering (IPO). The capital raised in the IPO will accelerate the development … Continued

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

By API User

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by … Continued

Starpharma Holdings (ASX: SPL) Announces License Agreement with Genentech

By API User

● Starpharma will employ its proprietary DEP® platform technology to develop dendrimerdrug conjugates that incorporate Genentech medicines for certain oncology targets. ● Starpharma will commence development activities immediately and work exclusively with Genentech in relation to those targets. ● Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and is eligible … Continued

BioMedTech Incubator Program Delivered by Brandon BioCatalyst’s CUREator and CSIRO Opens New Funding Round

By API User

Wednesday 8 October 2025: The $33 million BioMedTech incubator (BMTI) program delivered by Brandon BioCatalyst’s CUREator has opened its first funding round and is seeking expressions of interest from early-stage Australian biotech startups developing novel therapies with strong commercial potential across the discovery, preclinical, and clinical development stages. Funded by the Australian Government’s $20 billion … Continued

NeuroScientific Biopharmaceuticals (ASX:NSB) Gains TGA Approval for First Patients in Special Access Program for StemSmart(TM) Crohn’s Disease Therapy

By API User

7 October 2025 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced that the first three patients have been approved for treatment under the Therapeutic Goods Administration (TGA)’s Special Access Program to receive its patented stem cell therapy, StemSmart™, to treat fistulising Crohn’s disease.  The patients are now part of Cohort 1 for … Continued

LTR Pharma (ASX:LTP) Boosts Stake in LevOmega to 43% with New $1m Strategic Investment to Accelerate Sustainable Omega-3 Development

By API User

6 October 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) has increased its ownership in LevOmega Pty Ltd from 33% to ~43% via a strategic $1 million investment. The additional stake was acquired via the Company’s wholly-owned subsidiary, LTR Spectrum Pty Ltd, and follows LevOmega’s successful capital raising to progress its research and development … Continued

CAR-T EXOSOME AND EXO-ACE DATA PUBLISHED IN PEER REVIEWED JOURNAL

By API User

Key Facts: ·        INOVIQ’s proprietary EXO-ACE platform for scalable CAR-exosome production platform published in Journal of Visualized Experiments (JoVE) ·        EGFR- and HER2-targeted CAR-T-exosomes demonstrated potent in-vitro cancer-killing activity in breast and myeloid leukemia cell lines ·        EXO-ACE validated for large-scale production of CAR-EVs, supporting preclinical development INOVIQ Limited (ASX: IIQ) (“INOVIQ” or “the Company“) … Continued

AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25

By API User

Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six abstracts at the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM), taking place October 4-8, 2025, in Barcelona, Spain. The abstracts present key insights into clinical study … Continued

INOVIQ LICENCES WORLDWIDE RIGHTS TO OVARIAN CANCER BIOMARKER IP FROM UNIQUEST

By API User

Key Facts: ·         Exclusive worldwide licence secured from UniQuest for novel exosomal ovarian cancer biomarker IP ·         Supports development and commercialisation of INOVIQ’s EXO-OC test for early detection and screening ovarian cancer in asymptomatic women ·         Commercial discussions underway with leading clinical laboratories and diagnostic companies to accelerate US LDT launch ·         Clinical validation advancing, … Continued